Vicore Pharma Holding AB (publ) VCRE
As ofNov 16, 2026, 12:55 PM EST
- YTD
- -35.20%
- 1 year
- -35.20%
- Market cap
- 299.11M
- EPS (ttm)
- -2.04
- Shares out
- 28.15M
- YTD return
- -35.20%
- 1-year return
- -35.20%
- 50-day average
- 12.28
- 200-day average
- 12.28
- Revenue growth
- -32.50%
- Volume
- 9.81K
- Avg volume
- 22.87K
- Open
- 10.78
- Previous close
- 10.36
- Day's range
- 10.49 – 10.78
- 52-week range
- 7.88 – 17.80
- Beta
- 0.12
- Price target
- 35.42 (+236.4%)
5D +1.00 (+9.71%)
Key statistics
- Free cash flow
- -241.98M
- Return on equity
- -47.19%
Fundamental scorecard
4 of 25 checks passed on VCRE’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Mar 31, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 21, 2026 | Sep 30, 2026 | -0.04211 | — | — | — |
| May 6, 2026 | Jun 30, 2026 | -0.0505 | -0.04103 | +0.01 | +18.75% |
| Feb 27, 2026 | Mar 31, 2026 | -0.04923 | -0.05843 | -0.01 | -18.69% |
| Nov 5, 2025 | Sep 30, 2025 | -0.05189 | -0.05348 | 0.00 | -3.06% |
| May 6, 2025 | Jun 30, 2025 | -0.04365 | — | — | — |
| Feb 27, 2025 | Mar 31, 2025 | -0.03211 | -0.0459 | -0.01 | -42.95% |
About Vicore Pharma Holding AB (publ)
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Sweden
- Website
- vicorepharma.com
News
Your note
Sign in to keep a note on VCRE — it syncs with the Stock Master app.
